Form 8-K Vera Therapeutics, Inc. For: Jun 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Wolfe Research: 'VERA's continued weakness is creating a favorable setup into the July 7th PDUFA'
June 2, 2026 12:28 PM EDTWolfe Research analyst Andy Chen reiterated an Outperform rating and $88.00 price target on Vera Therapeutics (NASDAQ: VERA)
The analyst comments "Fundamentally positive Vera for a few reasons (i) normally, Vera would need 96- week eGFR stabilization data to achieve full approval. In our view, this lowers the risk of eGFR failure, precluding the... More
